Related references
Note: Only part of the references are listed.miR-383 inhibits hepatocellular carcinoma cell proliferation via targeting APRIL
Lin Chen et al.
TUMOR BIOLOGY (2016)
Inhibition of the miR-155 target NIAM phenocopies the growth promoting effect of miR-155 in B-cell lymphoma
Izabella Slezak-Prochazka et al.
ONCOTARGET (2016)
Human Leukemic Cells performing Oxidative Phosphorylation (OXPHOS) Generate an Antioxidant Response Independently of Reactive Oxygen species (ROS) Production
Abrar Ul Haq Khan et al.
EBIOMEDICINE (2016)
ROBO3 promotes growth and metastasis of pancreatic carcinoma
Shilong Han et al.
CANCER LETTERS (2015)
High circulating microRNA-122 expression is a poor prognostic marker in patients with hepatitis B virus-related hepatocellular carcinoma who undergo radiofrequency ablation
Hyo Jung Cho et al.
CLINICAL BIOCHEMISTRY (2015)
Down-regulation of 5S rRNA by miR-150 and miR-383 enhances c-Myc-rpL11 interaction and inhibits proliferation of esophageal squamous carcinoma cells
Xinyu Wang et al.
FEBS LETTERS (2015)
High intensity of cytoplasmic peroxiredoxin VI expression is associated with adverse outcome in diffuse large B-cell lymphoma independently of International Prognostic Index
Milla Elvi Linnea Kuusisto et al.
JOURNAL OF CLINICAL PATHOLOGY (2015)
Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation
Olaf Merkel et al.
JOURNAL OF PATHOLOGY (2015)
Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma
Xinchen Zhang et al.
MOLECULAR MEDICINE REPORTS (2015)
High serum microRNA-122 level is independently associated with higher overall survival rate in hepatocellular carcinoma patients
Yongqing Xu et al.
TUMOR BIOLOGY (2015)
The human miRNA repertoire of different blood compounds
Petra Leidinger et al.
BMC GENOMICS (2014)
In silico analysis of microRNA-510 as a potential oncomir in human breast cancer
Pawel Gaj et al.
BREAST CANCER RESEARCH (2014)
Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin Lymphoma
Kimberley Jones et al.
CLINICAL CANCER RESEARCH (2014)
Oxidative stress markers and mitochondrial antioxidant enzyme expression are increased in aggressive Hodgkin lymphomas
Hamid Bur et al.
HISTOPATHOLOGY (2014)
Peroxiredoxin proteins protect MCF-7 breast cancer cells from doxorubicin-induced toxicity
C. McDonald et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Diagnostic and prognostic significance of peroxiredoxin 1 expression in human hepatocellular carcinoma
Qi-Kai Sun et al.
MEDICAL ONCOLOGY (2014)
Nuclear Nrf2 expression is related to a poor survival in pancreatic adenocarcinoma
Y. Soini et al.
PATHOLOGY RESEARCH AND PRACTICE (2014)
The role of peroxiredoxin II in chemoresistance of breast cancer cells
Tieli Wang et al.
BREAST CANCER-TARGETS AND THERAPY (2014)
MiR-383 is Downregulated in Medulloblastoma and Targets Peroxiredoxin 3 (PRDX3)
Kay Ka-Wai Li et al.
BRAIN PATHOLOGY (2013)
MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma
Beatriz Sanchez-Espiridion et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma
Verena Koeberle et al.
EUROPEAN JOURNAL OF CANCER (2013)
Regulation of the Nrf2 antioxidant pathway by microRNAs: New players in micromanaging redox homeostasis
Xinghua Cheng et al.
FREE RADICAL BIOLOGY AND MEDICINE (2013)
Genetic and Epigenetic Down-regulation of MicroRNA-212 Promotes Colorectal Tumor Metastasis via Dysregulation of MnSOD
Xiangqi Meng et al.
GASTROENTEROLOGY (2013)
Proteomics study of open biopsy samples identifies peroxiredoxin 2 as a predictive biomarker of response to induction chemotherapy in osteosarcoma
Daisuke Kubota et al.
JOURNAL OF PROTEOMICS (2013)
Clinical Significance of Keap1 and Nrf2 in Oral Squamous Cell Carcinoma
Cong-Fa Huang et al.
PLOS ONE (2013)
MiRNAs Which Target CD3 Subunits Could Be Potential Biomarkers for Cancers
Fariborz Asghari Alashti et al.
PLOS ONE (2013)
Understanding the role of NRF2-regulated miRNAs in human malignancies
Niraj M. Shah et al.
ONCOTARGET (2013)
Expression of Peroxiredoxin 1, 2, 3, and 6 Genes in Cancer Cells during Drug Resistance Formation
E. V. Kalinina et al.
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE (2012)
Genetic Polymorphisms and Protein Expression of NRF2 and Sulfiredoxin Predict Survival Outcomes in Breast Cancer
Jaana M. Hartikainen et al.
CANCER RESEARCH (2012)
MicroRNA-23b downregulates peroxiredoxin III in human prostate cancer
Hui-chan He et al.
FEBS LETTERS (2012)
Prdx1 deficiency in mice promotes tissue specific loss of heterozygosity mediated by deficiency in DNA repair and increased oxidative stress
Vamsi Rani et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2012)
VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1α/VEGF and β-catenin/Tcf-4 signaling
Lingchao Chen et al.
NEURO-ONCOLOGY (2012)
Lymphoma cells with increased anti-oxidant defenses acquire chemoresistance
Margaret E. Tome et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2012)
How I treat relapsed and refractory Hodgkin lymphoma
John Kuruvilla et al.
BLOOD (2011)
MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism
Muhua Yang et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Regulation of NF-E2-Related Factor 2 Signaling for Cancer Chemoprevention: Antioxidant Coupled with Antiinflammatory
Rong Hu et al.
ANTIOXIDANTS & REDOX SIGNALING (2010)
Discovery of the Negative Regulator of Nrf2, Keap1: A Historical Overview
Ken Itoh et al.
ANTIOXIDANTS & REDOX SIGNALING (2010)
microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease
Carolyn Sangokoya et al.
BLOOD (2010)
Nrf2 and Keap1 Abnormalities in Non-Small Cell Lung Carcinoma and Association with Clinicopathologic Features
Luisa M. Solis et al.
CLINICAL CANCER RESEARCH (2010)
Proteomic identification of microRNA-122a target proteins in hepatocellular carcinoma
Shu Diao et al.
PROTEOMICS (2010)
Biological reactive intermediates that mediate dacarbazine cytotoxicity
Jalal Pourahmad et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity
Juxiang Cao et al.
EMBO JOURNAL (2009)
Hodgkin Lymphoma Cell Lines Are Characterized by a Specific miRNA Expression Profile
Johan H. Gibcus et al.
NEOPLASIA (2009)
RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy
Anju Singh et al.
CANCER RESEARCH (2008)
Decreasing peroxiredoxin II expression decreases glutathione, alters cell cycle distribution, and sensitizes glioma cells to ionizing radiation and H2O2
Pameeka S. Smith-Pearson et al.
FREE RADICAL BIOLOGY AND MEDICINE (2008)
Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies
Peeter Karihtala et al.
APMIS (2007)
Tumor-targeted induction of oxystress for cancer therapy
J. Fang et al.
JOURNAL OF DRUG TARGETING (2007)
Inhibitory role of peroxiredoxin II (Prx II) on cellular senescence
YH Han et al.
FEBS LETTERS (2005)
T-cell receptor signal transmission: who gives an ITAM?
LA Pitcher et al.
TRENDS IN IMMUNOLOGY (2003)
Regulation of constitutive TCR internalization by the ζ-chain
U D'Oro et al.
JOURNAL OF IMMUNOLOGY (2002)
CD20-mediated apoptosis: signalling through lipid rafts
JP Deans et al.
IMMUNOLOGY (2002)
Pleiotropic signal transduction mediated by human CD30:: A member of the tumor necrosis factor receptor (TNFR) family
C Schneider et al.
LEUKEMIA & LYMPHOMA (2002)
Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma
VL Kinnula et al.
JOURNAL OF PATHOLOGY (2002)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
Crystal structure of human peroxiredoxin 5, a novel type of mammalian peroxiredoxin at 1.5 Å resolution
JP Declercq et al.
JOURNAL OF MOLECULAR BIOLOGY (2001)
Peroxiredoxin IV is a secretable protein with heparin-binding properties under reduced conditions
A Okado-Matsumoto et al.
JOURNAL OF BIOCHEMISTRY (2000)
Share Paper
